United Kingdom: AstraZeneca’s COVID-19 vaccine is being withdrawn globally as a result of a “surplus of available updated vaccines” that target novel viral variations.
The news comes after the pharmaceutical business decided to voluntarily remove its marketing authorization from the European Union in March. This authorization allows the company to sell medicines in member states.
The vaccine is no longer authorized for use, according to a notice published by the European Medicines Agency on May 7.
AstraZeneca said in a statement that the choice was made in light of the availability of several more recent vaccinations that have been modified to specifically target COVID-19 variations. The AstraZeneca vaccine is no longer produced or supplied as a result of the fall in demand.
“According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over 3bn doses were supplied globally,” the statement said.
“Our efforts have been recognized by governments around the world and are widely regarded as being a critical component of ending the global pandemic. We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the COVID-19 pandemic,” according to the statement.
The vaccination is no longer being supplied by other nations. Due to the broad availability of more recent vaccinations, its usage was already being phased down starting in June 2021, however, it has not been accessible for use in Australia since March 2023.
In 2021, AstraZeneca renamed the COVID vaccination as Vaxzevria. The vaccination was approved for use in adults over the age of eighteen. It was administered in two doses, typically three months apart, into the upper arm muscle. Certain nations also utilized it as a booster shot.
Vaxzevria is a virus composed of another member of the adenovirus family that has been altered to carry the gene needed to produce a protein from the COVID-19-causing SARS-CoV-2 virus. The virus itself is not present in the vaccination, and thus cannot spread the infection.
Overall, the vaccination was determined to be safe and effective, but there was a chance of thrombosis with thrombocytopenia, or TTS, a rare but dangerous side event. Approximately two to three persons out of every 100,000 who received the Vaxzevria vaccine experienced the uncommon condition.
The World Health Organization’s most recent recommendation for COVID-19 vaccinations, released in April, stated that vaccine formulations should focus on the JN.1 lineage of the virus, which is replacing current XBB lineage variants.
POPULAR | Oxford University begins Nipah vaccine human trials
